Innate immune pattern-recognition receptors engaged by beta-glucan

Class

Polysaccharide immunomodulator (beta-glucan extract of Grifola frondosa / maitake mushroom)

Pathway

Innate immune activation / myelopoiesis support, used as an immunomodulatory combination agent in NSCLC chemotherapy

Notes

original target text: Innate immune pattern-recognition receptors engaged by beta-glucan (e.g. Dectin-1/complement receptor 3; canonical beta-glucan receptors)

Beta-glucans are branched polysaccharides derived from fungal or plant cell walls that are recognized by pattern-recognition receptors of the innate immune system, most notably Dectin-1 and complement receptor 3 (CR3), both expressed on macrophages, dendritic cells, and neutrophils. These receptors evolved to detect fungal cell-wall components as a danger signal, and their engagement triggers phagocytosis, cytokine release, and activation of myeloid cells more broadly. Pharmacologically, beta-glucan extracts are used to stimulate this innate immune activation and to support myelopoiesis, the production of new white blood cells in bone marrow, which is relevant in settings where chemotherapy suppresses the immune system. In oncology, engaging Dectin-1 and CR3 simultaneously is thought to prime myeloid cells for enhanced tumor cell clearance while also opsonizing tumor cells for complement-mediated attack, an effect that neither receptor alone would achieve as completely. This mechanism is broadly relevant to conditions involving impaired innate immunity or myelosuppression, including as a supportive or combination approach alongside cytotoxic chemotherapy in solid tumors such as non-small cell lung cancer, where restoring innate immune competence may help offset treatment-related immune suppression.